Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB)
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Bortezomib (Primary)
- Indications Myasthenia gravis; Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Proof of concept; Therapeutic Use
- Acronyms TAVAB
- 16 Nov 2019 Status changed from recruiting to discontinued.
- 28 Nov 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 28 Nov 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.